scholarly journals A Case of 10-Year Survival after Adrenalectomy for Isolated Adrenal Metastasis of Breast Cancer

Reports ◽  
2020 ◽  
Vol 3 (3) ◽  
pp. 22
Author(s):  
Tsuyoshi Nakagawa ◽  
Goshi Oda ◽  
Akihiro Yano ◽  
Hiroshi Kawachi ◽  
Hiroyuki Uetake
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Metastasis ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Breast Cancer Metastasis ◽  
Adrenal Metastasis ◽  
Pathological Examination ◽  
Endoscopic Adrenalectomy ◽  
Axillary Lymphadenectomy

Isolated adrenal metastasis of breast cancer is very rare, so adrenalectomy for breast cancer metastasis is rarely performed. The case of a breast cancer patient with five-year survival after resection of a left isolated adrenal metastasis is presented. A 70-year-old woman underwent left modified radical mastectomy and axillary lymphadenectomy for invasive ductal carcinoma (T2N1M0) 9 years earlier. At regular follow-up, a left adrenal mass, 4 cm in diameter, was seen on ultrasound examination and computed tomography (CT). Endoscopic adrenalectomy was performed. Pathological examination confirmed isolated adrenal metastasis of breast cancer. After surgery, hormone therapy was given for 5 years. Ten years after adrenalectomy, no metastatic lesions in other organs have been found on CT. Adrenalectomy for a metastatic adrenal tumor of breast cancer may provide survival benefits when combined with systemic hormone therapy and chemotherapy, particularly in patients with disease confined to the adrenal glands.

scholarly journals Rare Metastases in Colorectum of Infiltrating Ductal Breast Cancer: A Rare Case Report and Review

2020 ◽  
Author(s):  
Zhijun Zhang ◽  
Tao Li ◽  
Yuemin Li ◽  
Dongxu Li ◽  
Kai Zhang
Keyword(s):  
Breast Cancer ◽  
Cancer Metastasis ◽  
Ductal Carcinoma ◽  
Therapeutic Option ◽  
Radical Mastectomy ◽  
Left Breast ◽  
Breast Cancer Metastasis ◽  
Positron Emission ◽  
Rare Case Report ◽  
Lost To Follow Up

Abstract Background: Breast ductal carcinoma hardly metastasizes to colorectum and the effect of surgery is controversial. We treated one case of patients with breast ductal carcinoma metastasizes to colorectum with surgery and discussed current management experience of breast cancer metastasizing to colorectum by reviewing the literature. Case Presentation: A 37-year-old woman underwent a modified radical mastectomy three years ago for right breast cancer and developed left breast cancer with right breast cancer suspiciously metastasizing to colorectum, left ovary along with oviduct, pancreas, and left acetabulum according to positron emission tomography-computed tomography. Then she had chosen to give up further therapy but was admitted to our department complaining of shapeless feces and mucus pus and blood in stool for 2 years with the process of aggravating symptoms for recent 2 months. Colonoscopy revealed the existence of colorectal carcinoma. She received laparoscopic combined abdominal perineal resection and bilateral ovarian salpingectomy. Postoperative pathology as well as immunohistochemistry supported the origin of primary breast infiltrating ductal cancer. She remained tamoxifen therapy and was alive until she was lost to follow-up.Conclusions: Clinicians must pay attention to any gastro-intestinal symptoms of patients with a medical history of breast cancer since the incipient symptoms of breast cancer metastasis to colorectum are insidious. Definite diagnosis may be difficult even by endoscopy. Surgery should be considered as a therapeutic option and definite diagnostic means combined with immunohistochemistry.

Serum ANGPTL2 Levels Reflect Clinical Features of Breast Cancer Patients: Implications for the Pathogenesis of Breast Cancer Metastasis

2014 ◽  
Vol 29 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Motoyoshi Endo ◽  
Yutaka Yamamoto ◽  
Masahiro Nakano ◽  
Tetsuro Masuda ◽  
Haruki Odagiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Features ◽  
Cancer Progression ◽  
Breast Cancer Cells ◽  
Cancer Metastasis ◽  
Ductal Carcinoma ◽  
Breast Cancer Metastasis ◽  
Breast Cancer Patients

Introduction Breast cancer is a leading cause of cancer-related death in women worldwide, and its metastasis is a major cause of disease mortality. Therefore, identification of the mechanisms underlying breast cancer metastasis is crucial for the development of therapeutic and diagnostic strategies. Our recent study of immunodeficient female mice transplanted with MDA-MB231 breast cancer cells demonstrated that tumor cell-derived angiopoietin-like protein 2 (ANGPTL2) accelerates metastasis through both increasing tumor cell migration in an autocrine/paracrine manner, and enhancing tumor angiogenesis. To determine whether ANGPTL2 contributes to its clinical pathogenesis, we asked whether serum ANGPTL2 levels reflect the clinical features of breast cancer progression. Methods We monitored the levels of secreted ANGPTL2 in supernatants of cultured proliferating MDA-MB231 cells. We also determined whether the circulating ANGPTL2 levels were positively correlated with cancer progression in an in vivo breast cancer xenograft model using MDA-MB231 cells. Finally, we investigated whether serum ANGPTL2 levels were associated with clinical features in breast cancer patients. Results Both in vitro and in vivo experiments showed that the levels of ANGPTL2 secreted from breast cancer cells increased with cell proliferation and cancer progression. Serum ANGPTL2 levels in patients with metastatic breast cancer were significantly higher than those in healthy subjects or in patients with ductal carcinoma in situ or non-metastatic invasive ductal carcinoma. Serum ANGPTL2 levels in patients negative for estrogen receptors and progesterone receptors, particularly triple-negative cases, reflected histological grades. Conclusions These findings suggest that serum ANGPTL2 levels in breast cancer patients could represent a potential marker of breast cancer metastasis.

Interleukin 6 signal transducer, IL6ST correlates with survival outcomes in invasive ductal carcinoma

2021 ◽  
Author(s):  
Glen Foley ◽  
George Brock ◽  
Taylan Burke
Keyword(s):  
Breast Cancer ◽  
Survival Data ◽  
Interleukin 6 ◽  
Cancer Metastasis ◽  
Ductal Carcinoma ◽  
The United States ◽  
Breast Cancer Metastasis ◽  
Survival Outcomes ◽  
Signal Transducer ◽  
Transcriptome Data

In the United States, breast cancer is the most common cause of mortality among women (1). Breast cancer metastasis, or the spread of cancer from the breast to other organs such as the bones, liver, brain, and lungs, is the leading cause of death in women (2). We combined two separate microarray datasets, one containing transcriptome data from primary breast tumors (3) and the other containing transcriptome data from metastases in women with breast cancer (4), both of which included survival data for the patient from whom each tumor or metastasis sample was obtained. We discovered that the gene encoding the Interleukin 6 signal transducer, IL6ST, gp130 (5), was among the genes whose expression was most variable between patients who lived longer or less than 18 months by comparing tumor transcriptome data depending on survival outcomes. IL6ST was expressed at considerably higher levels in both original breast cancers and metastases in women who survived more than 18 months. These findings support the use of IL6ST as a biomarker or prognostic indicator (6-8) to help determine which women will benefit from more or less intensive treatment regimens based on metastasis prediction; additionally, IL6ST may be fundamentally linked to tumor progression and tumor aggressiveness, implying that IL6ST could be used as a therapeutic target in breast cancer.

scholarly journals Breast cancer metastasis to the conjunctiva

2013 ◽  
Vol 70 (3) ◽  
pp. 331-334 ◽  
Author(s):  
Anica Bobic-Radovanovic ◽  
Dejan Rasic ◽  
Marko Buta ◽  
Radan Dzodic
Keyword(s):  
Breast Cancer ◽  
Female Patient ◽  
Cancer Metastasis ◽  
Lobular Carcinoma ◽  
Hepatic Metastases ◽  
Radical Mastectomy ◽  
Excisional Biopsy ◽  
Breast Cancer Metastasis ◽  
Bulbar Conjunctiva ◽  
Conjunctival Lesion

Introduction. Conjunctival metastasis is exceedingly rare, and it is, as a rule, a sign of advanced malignant disease with poor prognosis. We presented a female patient with breast cancer metastasis to the conjunctiva. Case report. A 45-yearold premenopausal female patient was presented with a solitary, yellowish, thin, demarcated lesion in the superior nasal quadrant of the bulbar conjunctiva of the left eye noted by chance a week earlier. There was no sign of irritation, and no pain, and no other functional or morphological problem in either eye or orbit. Five years before the appearance of conjunctival metastasis, breast carcinoma was diagnosed and the patient underwent chemotherapy, preoperative radiotherapy and radical mastectomy. Three years later, computed tomography scan showed metastasis in the left hepatic lobe with ascites and the patient underwent chemotherapy again. But, four months prior to the appearance of conjunctival lesion body scintigraphy showed multifocal sceletal lesions and nuclear magnetic resonance revealed diffuse hepatic metastases and bilateral ovarial tumors. Paliative radiotherapy and hormonal therapy (megestrol, 160 mg) were carried out. An excisional biopsy of the observed conjunctival lesion was performed under topical anesthesia and the material was subjected to histopathological (HP) examination. HP and immunohistochemical examinations established the presence of breast infiltrating lobular carcinoma metastatic to the conjunctiva. The patient showed rapid deterioration after intervention, and died after three weeks. Conclusion. A survival period less than one month after the appearance of conjunctival metastasis deserves attention because it is unexpected and has never been reported previously. It is not a rule that HP presentation of a metastatic lesion is so characteristic that it is possible to determine a primary tumor.

scholarly journals Breast Cancer Metastasis to the Stomach That Was Diagnosed after Endoscopic Submucosal Dissection

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Masahide Kita ◽  
Masashi Furukawa ◽  
Masaya Iwamuro ◽  
Keisuke Hori ◽  
Yoshiro Kawahara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endoscopic Submucosal Dissection ◽  
Cancer Metastasis ◽  
Radical Mastectomy ◽  
Breast Cancer Metastasis ◽  
Signet Ring Cell ◽  
Axillary Lymph ◽  
Submucosal Dissection ◽  
Greater Curvature ◽  
Cystic Disease Fluid Protein

A 52-year-old woman presented with stage IIB primary breast cancer (cT2N1M0), which was treated using neoadjuvant chemotherapy (epirubicin, cyclophosphamide, and paclitaxel). However, the tumor persisted in patchy areas; therefore, we performed modified radical mastectomy and axillary lymph node dissection. Routine endoscopy at 8 months revealed a depressed lesion on the gastric angle’s greater curvature, and histology revealed signet ring cell proliferation. We performed endoscopic submucosal dissection for gastric cancer, although immunohistochemistry revealed that the tumor was positive for estrogen receptor, mammaglobin, and gross cystic disease fluid protein-15 (E-cadherin-negative). Therefore, we revised the diagnosis to gastric metastasis from the breast cancer.

scholarly journals Occult Breast Cancer

2018 ◽  
Vol 2 (4) ◽  
pp. 239
Author(s):  
Aslihan Kul ◽  
Ahmet Aydin Taşgın ◽  
Tuce Soylemez ◽  
Begumhan Baysal ◽  
Hakan Baysal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Metastasis ◽  
Imaging Techniques ◽  
Radical Mastectomy ◽  
Breast Cancer Metastasis ◽  
Cancer Type ◽  
Rare Type ◽  
Biopsy Material ◽  
Old Patients ◽  
Occult Breast Cancer

Today breast cancer is the most common cancer type in women, in both developed and developing countries. However, occult breast cancer is a highly rare type in all breast cancers. For the first time in history to know, Halsted defined the term “occult breast cancer” with 2 cases of his’ in the journal, Annals of Surgery. We have 2 similar cases who were 52 and 61-years-old patients and presented our clinic with left axillary swelling and pain. On physical examination and with imaging techniques there wasn’t any primary lesion found. Examination of lymph nodes’ biopsy material was compatible with breast cancer metastasis for both of the patients and they were diagnosed with occult breast cancer. They underwent a modified radical mastectomy surgery and axillary curettage. Histopathologic examination of the excised breast material revealed T1 invasive breast cancer.International Journal of Human and Health Sciences Vol. 02 No. 04 October’18. Page : 239-243

scholarly journals TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer

Cancers ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 210 ◽  
Author(s):  
Ming-Yang Wang ◽  
Hsin-Yi Huang ◽  
Yao-Lung Kuo ◽  
Chiao Lo ◽  
Hung-Yu Sun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Cancer Metastasis ◽  
Rna Binding ◽  
Tamoxifen Resistance ◽  
Breast Cancer Metastasis ◽  
Tamoxifen Treatment ◽  
Breast Cancers

Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers. Although patients who receive tamoxifen therapy benefit with respect to an improved overall prognosis, resistance and cancer recurrence still occur and remain important clinical challenges. A recent study identified TAR (HIV-1) RNA binding protein 2 (TARBP2) as an oncogene that promotes breast cancer metastasis. In this study, we showed that TARBP2 is overexpressed in hormone therapy-resistant cells and breast cancer tissues, where it enhances tamoxifen resistance. Tamoxifen-induced TARBP2 expression results in the desensitization of ER+ breast cancer cells. Mechanistically, tamoxifen post-transcriptionally stabilizes TARBP2 protein through the downregulation of Merlin, a TARBP2-interacting protein known to enhance its proteasomal degradation. Tamoxifen-induced TARBP2 further stabilizes SOX2 protein to enhance desensitization of breast cancer cells to tamoxifen, while similar to TARBP2, its induction in cancer cells was also observed in metastatic tumor cells. Our results indicate that the TARBP2-SOX2 pathway is upregulated by tamoxifen-mediated Merlin downregulation, which subsequently induces tamoxifen resistance in ER+ breast cancer.

scholarly journals BREAST CANCER METASTASIS TO THE THYROID GLAND: A RARE CASE REPORT WITH DIAGNOSTIC DILEMM

2020 ◽  
pp. 1-2
Author(s):  
Rajneesh Rawat ◽  
Sunil M Lanjewar ◽  
Mrinalini M Borkar ◽  
Jyoti Baghel
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Thyroid Gland ◽  
Cancer Metastasis ◽  
Ductal Carcinoma ◽  
Metastatic Lesion ◽  
Breast Cancer Metastasis ◽  
Breast Lump ◽  
Rare Case Report ◽  
Simple Mastectomy

Introduction: Metastasis to thyroid gland is very rare; with breast cancer metastasizing to thyroid is extremely rare. Here, we report a case of metastatic lesion in the thyroid from breast carcinoma in a 43 year old female who presented to us with a right breast lump for 1.5 years along with thyroid swelling for 6 months. Results: FNAC of breast lump showed ductal carcinoma while FNAC of thyroid nodule was inconclusive. CECT showed right breast neoplasm with malignant deposits in isthmus of thyroid. She underwent right simple mastectomy with axillary clearance and total thyroidectomy followed by chemotherapy. Histopathology analysis showed invasive ductal carcinoma in isthmus of thyroid.This was confirmed by immunohistochemistry, which revealed positive for GATA- 3and negative for TTF1 and Calcitonin. Conclusion: This case report highlights the importance of a correct early diagnostic work up.Immunohistochemical panels are helpful in differentiating between primary and secondary tumors.Also, thyroidectomy may be beneficial for local disease control and prevent the potential morbidity of tumor extension related to airway.

scholarly journals Meningioma as the host for metastatic breast cancer: A rare occurrence with important therapeutic impact

2021 ◽  
Vol 12 ◽  
pp. 314
Author(s):  
Mohammad Hosseinzadeh ◽  
Seyed Mehdi Ketabchi ◽  
Seyed Ali Ahmadi ◽  
Kasra Hendi ◽  
Maysam Alimohamadi
Keyword(s):  
Breast Cancer ◽  
Cancer Metastasis ◽  
Metastatic Breast ◽  
Radical Mastectomy ◽  
Rare Condition ◽  
Breast Cancer Metastasis ◽  
Histopathological Study ◽  
Metastatic Tumors ◽  
History Of ◽  
High Index Of Suspicion

Background: Tumor-to-tumor metastasis is a rare condition. There are few reports of metastatic tumors within intracranial tumors, including meningiomas. Since some metastatic tumors have osteoblastic imaging pattern, it is not always easy to differentiate them from meningioma on preoperative studies. Case Description: A 60-year-old female referred to our center complaining about a progressive headache, nausea, and vomiting for the past month. She had a history of breast cancer treated with radical mastectomy (5 years ago) and adjuvant chemotherapy (until 1 year ago). Workups revealed a dural-based mass in the left temporobasal and midline subfrontal regions. Histopathological study showed breast cancer metastasis nests within the primary meningioma. Conclusion: As the diagnosis of metastatic nests inside a benign tumor, drastically alters postoperative adjuvant treatments, a high index of suspicion is needed evaluating tumors from patients with a history of systemic neoplasms.

Sign in / Sign up

Export Citation Format

Share Document